---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-069077"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2024-06-05T23:59:59+00:00"
generated_at: "2026-06-01T06:16:05.724310+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Axsome settles Sunosi patent litigation with Unichem; generic entry June 30, 2042

## Summary
- Settlement resolves Hatch-Waxman litigation over Sunosi (solriamfetol) following Unichem's ANDA.
- Unichem may begin selling generic Sunosi on June 30, 2042, subject to pediatric exclusivity extension.
- Agreement subject to FTC and DOJ review; other Sunosi patent cases remain pending in New Jersey.
- Axsome maintains Sunosi exclusivity until at least 2042 unless earlier triggering events occur.

## SEC filing metadata
- accession: 0000950170-24-069077
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2024-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017024069077/0000950170-24-069077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017024069077/axsm-20240605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-069077
- JSON: https://secwatch.observer/filing/0000950170-24-069077.json
- Plain text: https://secwatch.observer/filing/0000950170-24-069077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.